BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 33.75
-0.20 (-0.59%)
Mar 24, 2026, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 4.2 billion as of March 24, 2026. Its market cap has increased by 0.68% in one year.
Market Cap
4.20B
Enterprise Value
3.70B
Revenue
222.34M
Ranking
n/a
PE Ratio
n/a
Stock Price
33.75
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 4.20B, an increase of 54.63%. That is a compound annual growth rate of 6.65%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 24, 2026 | 4.20B | -12.11% |
| Dec 31, 2025 | 4.78B | 14.21% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Pharmosa Biopharm | 5.11B |
| UnicoCell Biomed | 5.09B |
| OBI Pharma | 5.05B |
| Locus Cell | 4.96B |
| Senhwa Biosciences | 4.96B |
| Medigen Biotechnology | 4.63B |
| Energenesis Biomedical CO.,LTD. | 3.93B |
| Formosa Pharmaceuticals | 3.90B |